Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending May 10, 2015
Neoadjuvant Chemotherapy Rates in Breast Cancer, A review of patients from the National Cancer Database
Genetic Variant Predicts Earlier Lung Cancer Diagnosis, Meta-analysis links smoking cessation success and cancer risk to genes
NSCLC Systemic Therapy Rates , Review finds treatment rates increasing, but still low
Must reads for theWeek ending May 3, 2015
Hormone Replacement Therapy and Breast Cancer Risk, WHI trials review progestin plus estrogen and estrogen alone
Colorectal Cancer Screening With Flexible Sigmoidoscopy , A survival meta-analysis of Cochrane Reviews
Cancer Diagnosis and Smoking Cessation Rates, Quit rates not altered by cancer type or stage
Adjuvant Chemotherapy in NSCLC, VA study tests whether patient age matters
AGAI Guideline for Pancreatic Cysts, Strategy for identifying early invasive cancer
Must reads for theWeek ending April 26, 2015
BRCA1/2 Mutation Clusters Linked to Risk, Breast and ovarian cancer tied to specific genetic spans
CRP Levels Linked to Melanoma Outcomes, Inflammatory marker associated with survival rates
Does BPH Treatment Protect Against Cancer Deaths? , Use of 5-ARIs and risk of prostate cancer mortality
Genes Linked to Better Outcomes in AML , SWOG study identifies mutation linked to improved survival
Breast Cancer: Talking About Genetic Testing, Clarifying risks may ease patients’ minds
Must reads for theWeek ending April 19, 2015
Allergies, Atopic Dermatitis, and Melanoma, Risk of keratinocyte cancers influenced by allergy
Androgen Deprivation Therapy and Testosterone Levels, PR-7 trial finds link to cause-specific survival
Link Between Vitamin D and Lymphoma Survival, Analysis of patients in SWOG and LYSA trials
Breast Cancer Staging and Survival, Two-cohort study suggests changes to guideline
Must reads for theWeek ending April 12, 2015
Clinical Guideline: Treating Pediatric Hodgkin Lymphoma, New ILROG report aims to minimize late side effects
NCI Annual Report Adds Breast Cancer Subtypes, Prognosis and treatment varies by HR/HER2 status
Nivolumab or Chemotherapy for Melanoma Treatment?, Interim analysis from the phase 3 CheckMate 037
Improving Breast Cancer Risk Prediction, New approach to BI-RADS breast density model
Predicting Survival in Gastric Cancer, Which classification system is most accurate?